{Reference Type}: Case Reports
{Title}: Ameloblastic Fibrosarcoma of the Jaw: Case Report, Genetic Profiling, and Literature Review.
{Author}: Barakeh D;Alsolami A;Abedalthagafi M;
{Journal}: Case Rep Oncol
{Volume}: 16
{Issue}: 1
{Year}: 2023 Jan-Dec
暂无{DOI}: 10.1159/000532014
{Abstract}: Ameloblastic fibrosarcoma (AFS) is considered a malignant progression resulting from dysplastic changes in an ameloblastic fibroma (AF). Both tumors are extremely rare, with only a few cases reported in the scientific literature. Notably, BRAF mutations have been identified in ameloblastomas, suggesting a connection between ameloblastic morphology and BRAF mutations, as AF is believed to be the precursor neoplasm leading to AFS. In this study, we present a case of AFS in a 25-year-old male. The tumor tissue underwent molecular analysis, specifically next-generation sequencing (NGS) using the Oncomine Comprehensive Assay v3 System. The analysis revealed pathogenic mutations in TP53 and RB genes, as well as copy number gains in NTRK1, MDM4, and BRAF. Additionally, we provide a summary of the literature's findings from the analysis of 107 previously reported AFS cases. Our findings suggest the existence of a molecularly distinct subtype, emphasizing the importance of comprehensive molecular testing for these patients.